Jaguar Health's Promising Results for Breast Cancer Patients at MASCC Annual Meeting

Jaguar Health, Inc. revealed significant findings from the OnTarget Phase 3 study focusing on breast cancer patients. Their drug, Mytesi® (crofelemer), was shown to achieve statistically significant results in managing diarrhea, a common side effect of cancer therapies. These results were highlighted in a poster at the San Antonio Breast Cancer Symposium and will be presented at the MASCC Annual Meeting.

Jaguar plans discussions with the FDA in mid-2025 to explore crofelemer's potential approval for these patients. This underscores the importance of supportive treatments to enhance patient quality of life while continuing cancer therapy.

Additionally, insights from a survey on oral mucositis in cancer treatment were accepted for MASCC presentation, highlighting patient experiences and needs.